Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Accumulated Expenses (2016 - 2022)

Historic Accumulated Expenses for Usana Health Sciences (USNA) over the last 10 years, with Q1 2022 value amounting to $32.4 million.

  • Usana Health Sciences' Accumulated Expenses rose 55.61% to $32.4 million in Q1 2022 from the same period last year, while for Jan 2022 it was $32.4 million, marking a year-over-year increase of 55.61%. This contributed to the annual value of $32.4 million for FY2022, which is 55.61% up from last year.
  • Usana Health Sciences' Accumulated Expenses amounted to $32.4 million in Q1 2022, which was up 55.61% from $32.2 million recorded in Q1 2021.
  • Usana Health Sciences' 5-year Accumulated Expenses high stood at $33.7 million for Q4 2018, and its period low was $26.2 million during Q4 2019.
  • Its 4-year average for Accumulated Expenses is $31.1 million, with a median of $32.3 million in 2021.
  • Per our database at Business Quant, Usana Health Sciences' Accumulated Expenses surged by 4712.56% in 2018 and then tumbled by 2240.62% in 2019.
  • Usana Health Sciences' Accumulated Expenses (Quarter) stood at $33.7 million in 2018, then decreased by 22.41% to $26.2 million in 2019, then increased by 23.07% to $32.2 million in 2021, then rose by 0.56% to $32.4 million in 2022.
  • Its Accumulated Expenses was $32.4 million in Q1 2022, compared to $32.2 million in Q1 2021 and $26.2 million in Q4 2019.